• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Data Review of 2 doses of Sonidegib in Advanced Basal Cell Carcinoma (BOLT Trial)

Opinion
Video

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Jonathan S Zager, MD, FACS, FSSO

Moffitt Cancer Center

Tampa, Florida

Lilia Correa-Selm, MD, FAAD, FACMS

Moffitt Cancer Center

Tampa, Florida

Aaron Farberg, MD

Bare Dermatology

Dallas, Texas

John Strasswimmer, MD, PhD

Florida Atlantic University

Delray Beach, Florida

Andrew Weinstein, MD, MPH, FAAD

Boynton Beach Skin, University of Miami

Boynton Beach and Coral Gables, Florida

Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.

Segment Description: Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.